- Evoke Pharma (NASDAQ:EVOK) jumps 8.4% premarket in reaction to the announcement that its US patent No. 11,020,361 for Gimoti (metoclopramide) nasal spray is now listed in the FDA's “Orange Book”.
- The patent covers methods of use for nasal delivery of metoclopramide for the treatment of gastroparesis and carries a patent term to at least 2029.
- The FDA approved the NDA for Gimoti in June 2020.
Evoke Pharma pops 8% after Gimoti listed in FDA Orange Book
Recommended For You
About EVOK Stock
Related Stocks
Symbol | Last Price | % Chg |
---|---|---|
EVOK | - | - |
Evoke Pharma, Inc. |